Replies to post #507897 on Anavex Life Sciences Corp (AVXL)

[Investor2014]

Right!

I am convinced that this drug, by pre specifying the ABCLEAR3 group in a new trial, will easily succeed in a new trial.

Where have you heard that before?

[Doc328]

Most likely, S1R will be second in the official hierarchy after the full cohort ITT and designated a formal subgroup endpoint. The company will need to figure out if they allot. Alternatively - if the company strongly feels this subgroup is superior AND that the Q2P variant fails to respond, then they can recruit this population only --- will lead to more screen failures but perhaps a better overall outcome. COL24A1 (ABCLEAR 2 and 1/2 of ABCLEAR3) will not be in the formal hierarchy but rather a per-specified exploratory analysis

The early exercise of options by Missling in Sept/Oct may have been the hint that things were not going AVXL's way

[Bourbon_on_my_cornflakes]

this drug, by pre specifying the ABCLEAR3 group in a new trial, will easily succeed in a new trial.

Too bad the glacial management pissed away YEARS instead of running more trials.